Health Public Hearing

COUNCIL OF THE DISTRICT OF COLUMBIA C O M M I T T E E O N H E A LT H NOTICE OF PUBLIC HEARING 1350 PENNSYLVANIA AVE., N.W., WASHINGTON, D.C. 20004 COUNCILMEMBER VINCENT C. GRAY, CHAIRPERSON T H E C O M M I T T E E O N H E A LT H ANNOUNCES A PUBLIC HEARING ON BILL 23-0326, THE "POSTPARTUM COVERAGE ACT OF 2019" BILL 23-0360, THE "CONTINUING NUTRITION EDUCATION AMENDMENT ACT OF 2019" BILL 23-0430, THE "ACCESS TO BIOSIMILARS AMENDMENT ACT OF 2019" W E D N E S D AY, N O V E M B E R 1 3 , 2 0 1 9 12:00 P.M., ROOM 412, JOHN A. WILSON BUILDING 1350 PENNSYLVANIA AVENUE, N.W. WASHINGTON, D.C. 20004 Councilmember Vincent C. Gray, Chairperson of the Committee on Health, announces a Public Hearing on Bill 23-0326, the "Postpartum Coverage Act of 2019", Bill 23-0360, the "Continuing Nutrition Education Amendment Act of 2019", and Bill 23-0430, the "Access to Biosimilars Amendment Act of 2019." The hearing will be held on Wednesday, November 13, 2019, at 12:00 p.m., or immediately following the Committee on Health and Committee on Education's joint hearing, in Room 412 of the John A. Wilson Building. This notice has been revised to reflect the removal of Bill 23-0416, the "Better Access for Babies to Integrated Equitable Services Act of 2019" from the hearing agenda. Bill 23-0326, the "Postpartum Coverage Act of 2019", extends postpartum inpatient and outpatient benefits to at least a year after childbirth. Bill 23-0360, the "Continuing Nutrition Education Amendment Act of 2019", requires continuing education for certain health occupations on the subject of nutrition. Bill 23-0430, the "Access to Biosimilars Amendment Act of 2019", authorizes licensed pharmacists to dispense interchangeable biological products, and requires notifications to physicians when such interchangeable biological products are dispensed. An interchangeable biological product is a biological product licensed by the US Food and Drug Administration to meet the standards of interchangeability under federal law and determined to be therapeutically equivalent by the USFDA. The Committee invites the public to testify at the roundtable. Those who wish to testify should contact Malcolm Cameron, Committee Legislative Analyst at (202) 654-6179 or mcameron@dccouncil.us, and provide your name, organizational affiliation (if any), and title with the organization, preferably by 5:00 p.m. on Monday, November 11,2019. Witnesses should bring 15 copies of their written testimony to the roundtable. The Committee allows individuals 3 minutes to provide oral testimony in order to permit each witness an opportunity to be heard. Additional written statements are encouraged and will be made part of the official record. Written statements may be submitted by e-mail to mcameron@dccouncil.us or mailed to: Council of the District of Columbia, 1350 Pennsylvania Ave., N.W., Suite 113, Washington D.C. 20004.